Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLU-554 (fisogatinib) + CS1001 (anti‑PD‑L1) in HCC
CTR20192296Phase 2Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fisogatinib, sugemalimab in hepatocellular carcinoma (HCC), sponsored by CStone Pharmaceuticals. Started Nov 2019; status: completed.
02
Drugs
fisogatinibsugemalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20192296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192296.